EANS-Adhoc: Marseille-Kliniken AG: Result improvement in business year 2011/2012

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

01.10.2012

Hamburg, 01 October 2012 - Marseille-Kliniken AG (Prime Standard,
ISIN DE0007783003, MKA) has achieved an increase in results in
business year 2011/2012 (1 July - 30 June). Revenues increased to EUR
195.1 million. EBIT increased to EUR 10.9 million, earnings per share
moved to EUR 0.45 (previous year EUR 0.20). Occupancy rate rose to
88.9%.

The core business "care for elderly and patients" in the segments
inpatient and outpatient still shows high vacancies, although total
occupancy rate has increased by almost 2% in the last business year.
At this point the company still has significant potential which has
not been made accessible yet.

The general skills shortage in Germany hinders the company from
rapidly improving capacity utilization in its facilities. Internal
reorganization including decentralization of the operational business
is not completed.

With the appointment of Dieter Wopen as new member of the management
board starting on 15 November 2012 the company shall insofar "gain
speed". The contract with chairman Michael Thanheiser was prematurely
prolonged until 31 March 2017.

The annual report 2011/2012 will be published on Monday, 08 October
2012.

end of ad-hoc-announcement ==========================================
====================================== About Marseille-Kliniken AG:

Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its
57 residential care facilities, three residential units for assisted
living and about 4,700 employees is a market leading listed company
on health care in Germany. The business model is significantly
influenced by the demographic development. Therefore
Marseille-Kliniken AG has a secured future. Short-term economic
fluctuations on the other hand exert only a minor influence. As a
consistently modern company with strong focus on quality, the private
enterprise is in a good position within a competitive environment
primarily characterized by regionally active charities.

Further inquiry note:
Hillermann Consulting
Jan Pahl
Investor Relations for Marseille-Kliniken AG
Poststraße 14-16
20354 Hamburg
Germany
Tel.: +49 - (0)40 / 3202791-0
www.marseille-kliniken.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10179 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: info@marseille-kliniken.de
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
Hamburg, regulated dealing/prime standard: Frankfurt
language: English